Yissum Research Development Company of the Hebrew University

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

Retrieved on: 
Friday, October 27, 2023

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for mirvetuximab soravtansine (ELAHERE®) for the treatment of patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for mirvetuximab soravtansine (ELAHERE®) for the treatment of patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  • We look forward to working closely with the EMA throughout the review process and to potentially bring this novel ADC to Europe as early as 2024."
  • In the MIRASOL trial, ELAHERE demonstrated statistically significant and clinically meaningful improvements in progression-free survival, objective response rate, and overall survival compared to investigator's choice (IC) of single-agent chemotherapy.
  • ELAHERE demonstrated a tolerable safety profile compared to IC chemotherapy consisting predominantly of low-grade ocular and gastrointestinal events.

Beyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder

Retrieved on: 
Monday, September 18, 2023

GARDEN CITY, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced the publication of new data that support ongoing preclinical development of selective nNOS inhibitors for the treatment of Autism Spectrum Disorder (ASD).

Key Points: 
  • The slow-release formulation led to reversal of behavioral phenotypes and the nitrosative stress of the Shank3 mouse model of autism.
  • The Hebrew University of Jerusalem (HUJI) has previously published studies suggesting that NO is a pathologic factor in ASD.
  • In previously published studies, 10-day daily injections of 7-nitroindazole (7-NI), a selective nNOS inhibitor, reversed the manifestations of ASD phenotype, and reversed nitrosative stress.
  • “These novel data provide new evidence of the role of nitric oxide in autism.

Innocan Pharma Announces Clinical Study Results: Evidence of Reduced Osteoarthritis Pain in Dogs After Liposomal CBD Injection

Retrieved on: 
Tuesday, August 29, 2023

Published in the Frontiers in Veterinary Science Journal, under the research topic "Use of Cannabis Derivatives in Veterinary Medicine" (the "Study").

Key Points: 
  • Published in the Frontiers in Veterinary Science Journal, under the research topic "Use of Cannabis Derivatives in Veterinary Medicine" (the "Study").
  • In the study, six dogs with naturally-occurring osteoarthritis, unresponsive to conventional medications, were treated with a single injection of five mg/kg liposomal-CBD (in addition to their routine medications).
  • The subsequent observations spanned six weeks and included measuring CBD plasma concentrations, blood work, collar activity data, and evaluations of well-being and pain.
  • The study underscores the effectiveness and increased bioavailability of LPT-CBD tested as part of a multimodal pain management in dogs with osteoarthritis.

Beyond Air® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD)

Retrieved on: 
Monday, August 7, 2023

GARDEN CITY, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced the presentation of data that support the ongoing preclinical development of selective neuronal nitric oxide synthase (nNOS) inhibibitors for the treatment of Autism Spectrum Disorder (ASD). These data will be presented by the Amal Lab from the Hebrew University of Jerusalem (HUJI) in a poster at the Annual International Society of Neurochemistry (ISN) and the European Society of Neurochemistry (ESN) meetings, which are being held in Portugal from August 8th - 11th.

Key Points: 
  • Research conducted recently at HUJI has shown that mutation in the CNTNAP2 gene increases NO formation in the brain of the ASD mouse model.
  • These data demonstrate that the inhibition of NO production may reverse ASD phenotypes, and provide further evidence that NO is a pathologic factor in autism.
  • These results have led researchers to believe that NO is a novel target for the treatment of ASD and other neurological disorders.
  • The preclinical data developed thus far show that this exciting novel approach to treating ASD has the potential to address a significant unmet medical need.

ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer

Retrieved on: 
Monday, July 31, 2023

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer, is stepping down from her position with the Company to take a well-deserved professional hiatus prior to pursuing new opportunities outside of ImmunoGen.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer, is stepping down from her position with the Company to take a well-deserved professional hiatus prior to pursuing new opportunities outside of ImmunoGen.
  • Dr. Berkenblit will continue with the Company through the end of August to support the transition of her responsibilities.
  • Michael Vasconcelles, MD, Executive Vice President, Research, Development, and Medical Affairs, will assume the role of Chief Medical Officer.
  • "Over the last eight years, Anna has played an essential role in the transformation of ImmunoGen," said Mark Enyedy, ImmunoGen's President and Chief Executive Officer.

Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome

Retrieved on: 
Friday, June 16, 2023

Tel Aviv, Israel / Vancouver, Canada, June 16, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that as part of the Company's ongoing collaboration with SciSparc Ltd. (NASDAQ: SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, it has entered into a research agreement with the Hebrew University of Jerusalem, to evaluate Clearmind's and SciSparc's combination treatment for obesity and metabolic syndrome.

Key Points: 
  • "We are excited to further investigate the effect of the combination of MEAI and PEA for treating obesity and metabolic syndrome.
  • Previous pre-clinical studies performed with our proprietary MEAI showed a very positive effect in treating obesity.
  • "The collaboration with SciSparc has already yielded numerous patent applications related to combination therapies for treating binge behaviors, cocaine addiction, depression and more."
  • The upcoming study will evaluate the effect of the combination of MEAI and PEA on food intake, metabolic and activity profiles.

Beyond Air® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem

Retrieved on: 
Thursday, June 15, 2023

GARDEN CITY, N.Y., June 15, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd.), today announced that it has entered into an agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, LTD. to license the commercial rights for multiple neuronal nitric oxide synthase (nNOS) inhibitor candidates, currently being developed for the treatment of autism spectrum disorder (ASD) and other neurological conditions. There are currently no therapies approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of ASD.

Key Points: 
  • There are currently no therapies approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of ASD.
  • The partial inhibition of nNOS reduces nitrosative stress biomarkers and reverses the molecular, synaptic and behavioral ASD-associated phenotypes.
  • Dr. Amal is an Assistant Professor at the Institute for Drug Research, Faculty of Medicine at the Hebrew University of Jerusalem.
  • He began his academic journey at the age of seventeen, with a degree in Pharmacy, from the Hebrew University.

Medigene AG Reports Full-Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 29, 2023

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the year ended December 31, 2022 and provided a corporate update.
  • General and administrative (G&A) expenses were EUR 7.7 million in 2022 compared to EUR 6.2 million in the year prior.
  • Research and development (R&D) expenses increased from EUR 12.8 million in 2021, to EUR 28.5 million in fiscal 2022.
  • Cash and cash equivalents amounted to EUR 22.2 million at the end of 2022, compared to EUR 22.4 million at the end of 2021.

ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents

Retrieved on: 
Wednesday, March 1, 2023

Following the research period for each target, Vertex will have the option to obtain a worldwide, exclusive license to research, develop, and commercialize conditioning agents employing ImmunoGen's technology for that target.

Key Points: 
  • Following the research period for each target, Vertex will have the option to obtain a worldwide, exclusive license to research, develop, and commercialize conditioning agents employing ImmunoGen's technology for that target.
  • ImmunoGen will retain full rights to the ADC technology for all targets not covered by the Vertex license.
  • ImmunoGen is eligible to receive up to $337 million in option exercise fees and development and commercial milestone payments per target.
  • ImmunoGen will be eligible to receive tiered royalties as a percentage of worldwide commercial sales of novel licensed targeted conditioning agents by Vertex.

Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

Retrieved on: 
Thursday, January 5, 2023

Tel Aviv, Israel / Vancouver, Canada, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced positive pre-clinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome.

Key Points: 
  • It included three groups of rodents: one was fed a standard diet, another a high-fat diet, and the third a high-fat diet group along with treatment with MEAI.
  • Additionally, MEAI treatment yielded normalization of insulin levels, improved glucose tolerance as well as reduced fat and triglycerides accumulation in the liver.
  • Thus, MEAI may be beneficial for the treatment of compulsive reward-seeking behavior or excessive consumption of sweet foods.
  • This underserved multibillion-dollar market creates significant opportunities for Clearmind to generate substantial revenues, should MEAI reach the market as an obesity treatment.